Ezallor Chart 40%
Approximately 40% of American adults cannot or will not swallow solid forms of medication.2 Sun LTC is committed to providing alternative formulations to address this need.

Ezallor Sprinkle

Choose from 3 administration options–each providing the same drug release.1


Swallow whole

Opened and Sprinkled

Open and sprinkle
over soft food

Via Nasogastric Tube

Administer via
nasogastric tube

No pill crushing. Just open, sprinkle, and serve.1

Ezallor Sprinkle™ provides the same drug release when it is swallowed whole, sprinkled over soft foods, or administered via nasogastric tube.1



Ezallor Sprinkle (rosuvastatin) capsules are indicated as an:

  • Adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia
  • Adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type III hyperlipoproteinemia)
  • Adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, total-C, and apoB in adult patients with homozygous familial hypercholesterolemia


Ezallor Sprinkle has not been studied in Fredrickson type I and V dyslipidemias. Ezallor Sprinkle is indicated only for use in patients 18 and older.



  • Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin.
  • Patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels.
  • Pregnancy: advise females of reproductive potential to use effective contraception during treatment with Ezallor Sprinkle.
  • Lactation: limited data indicate that rosuvastatin is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require Ezallor Sprinkle treatment should not breastfeed their infants.

Warnings and Precautions

  • Skeletal Muscle Effects: Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including rosuvastatin. These risks can occur at any dose level, but are increased at the highest dose (40 mg). Ezallor Sprinkle should be prescribed with caution in patients with predisposing factors for myopathy (e.g. aged ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with Ezallor Sprinkle may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir, or simeprevir. Ezallor Sprinkle therapy should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever, and if muscle signs and symptoms persist after discontinuing Ezallor Sprinkle.
  • Liver Enzyme Abnormalities: It is recommended that liver enzyme tests be performed before the initiation of Ezallor Sprinkle, and if signs or symptoms of liver injury occur. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with Ezallor Sprinkle, promptly interrupt therapy. If an alternate etiology is not found, do not restart Ezallor Sprinkle. Ezallor Sprinkle should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease. Active liver disease, which may include unexplained persistent transaminase elevations, is a contraindication to the use of Ezallor Sprinkle.
  • Concomitant Coumarin Anticoagulants: Caution should be exercised when anticoagulants are given in conjunction with Ezallor Sprinkle because of its potentiation of the effect of coumarin-type anticoagulants in prolonging the prothrombin time/INR. In patients taking coumarin anticoagulants and Ezallor Sprinkle concomitantly, INR should be determined before starting Ezallor Sprinkle and frequently enough during early therapy to ensure that no significant alteration of INR occurs.
  • Proteinuria and Hematuria: Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with rosuvastatin. These findings were more frequent in patients taking rosuvastatin 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on Ezallor Sprinkle therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.
  • Endocrine Effects: Increases in HbA1c and fasting serum glucose levels have been reported with statins, including rosuvastatin. Based on clinical trial data with rosuvastatin, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus.

Adverse Reactions

In the controlled clinical trials database, the most common adverse reactions were headache, myalgia, abdominal pain, asthenia, and nausea.

There have been rare reports of immune-mediated myopathy associated with statin use. There have been rare postmarketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

Please see Full Prescribing Information.

References: 1. Ezallor Sprinkle ™ [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc., 2020. 2. Center for Drug Evaluation and Research, US Food and Drug Administration. Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules: Guidance for Industry. www.fda.gov/media/87344/download. Published June 2015. Accessed July 16, 2020.

Back to Top